Treatment with Next-Generation ALK Inhibitors Fuels Plasma ALK Mutation Diversity

BACKGROUND: Acquired resistance to next-generation ALK tyrosine kinase inhibitors (TKIs) is often driven by secondary ALK mutations. Here we investigated utility of plasma genotyping for identifying ALK resistance mutations at relapse on next-generation ALK TKIs. METHODS: We analyzed 106 plasma spec...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Clin Cancer Res
Auteurs principaux: Dagogo-Jack, Ibiayi, Rooney, Marguerite, Lin, Jessica J., Nagy, Rebecca J., Yeap, Beow Y., Hubbeling, Harper, Chin, Emily, Ackil, Jennifer, Farago, Anna F., Hata, Aaron N., Lennerz, Jochen K., Gainor, Justin F., Lanman, Richard B., Shaw, Alice T.
Format: Artigo
Langue:Inglês
Publié: 2019
Sujets:
Article
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC6858956/
https://ncbi.nlm.nih.gov/pubmed/31358542
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-19-1436
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires